Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Downgrades Provention Bio to Neutral, Raises Price Target to $25

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Provention Bio (NASDAQ:PRVB) from Buy to Neutral and raises the price target from $16 to $25.
byBenzinga Newsdesk
March 15, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Provention Bio (NASDAQ:PRVB) from Buy to Neutral and raises the price target from $16 to $25.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Pfizer Provides Update On Ownership Interest In Haleon; Haleon To Become Publicly Listed Standalone Company In July; Pfizer Will Continue To Hold 32% Ownership In Haleon, Will Exit Ownership Interest In A ‘Disciplined Manner’

By Benzinga Newsdesk
June 1, 8:29 AM
Pfizer Provides Update on Ownership Interest in Haleon Haleon to Become a Publicly Listed Standalone Company in July Following a Demerger by GSK Post-Demerger, Pfizer Plans to Exit Ownership Interest in Haleon in a

GSK